Testosterone enanthate
As of the edition of 20 October 2026, Testosterone enanthate is a small molecule: marketed, first approved in 1952 (CH); acts on AR.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Small molecule
- Brand name
- Delatestryl
- First approved
- 9 July 1952 (CH)
- Approvals on record
- 7 in 3 regions
- Holder of the most recent approval
- Halozyme Therapeutics; 4 holders in all
- Registered trials
- 21, 2 stopped early
- Disease areas
- Urinary and reproductive; Hormones; Nervous system; Bones, joints and muscles; Cancer; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Testosterone enanthate.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| AR | Androgen receptor | P10275 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 12 | 7 | 4 | 1 |
| Phase 3 | 3 | 1 | 1 | 0 |
| Phase 4 | 3 | 2 | 0 | 1 |
| All trials | 21 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Endo | Acquired holder | 2013 to now |
| Halozyme Therapeutics | Later holder and Lead sponsor of trials | 2018 to now |
| Bristol Myers Squibb | Earlier holder |